File No CT/01/15 – DCG (I) Clinical Trial NOC No: - GCT/28/15

1892/19.01.15.

GOVERNMENT OF INDIA
Directorate General of Health Services
Central Drugs Standard Control Organization
Office of Drugs Controller General (India)
(Global Clinical Trial Division)
FDA Bhawan, Kotla Road, New Delhi-110002
Tel No: 01123236965, Fax: 01123236971
E-mail: dci@nic.in

File No: CT/01/15 – DCG (I) Date: 27/08/15

To,

M/s Novartis Healthcare Pvt. Ltd.,
Sandoz House,
Dr. Annie Besant Road, Worli,
Mumbai-400 018.

Subject: Permission for conducting a Phase IIIb clinical trial entitled "A multicenter study to evaluate safety and tolerability in patients with chronic heart failure and reduced ejection fraction from PARADIGM-HF receiving open label LCZ696"– regarding.

Reference: - Your letter No. NIL dated 16 Jan 2015 on the subject mentioned above.

Sir,

This Directorate has no objection to your conducting the subject mentioned clinical trial as per the provisions of Drugs & Cosmetics Rules under supervision of the following investigators and as per the **Protocol No: CLCZ696B2317 version v00 dated 10 Jul 2014** submitted to this Directorate.

1. Dr. Milind Lohkare, Shrikrishna Hrudayalaya and Critical Care centre, Congress Nagar Square, Tikekar Road, Dhantoli, Nagpur – 440 012.
2. Dr. Sandeep Kumar Gupta, M.V. Hospital and Research Centre, 314/30, Mirza Mandi, Chowk, Lucknow-226 003, Uttar Pradesh.
3. Dr. Pragnesh Shah, Apple Hospital, Udhna Darwaja, Ring Road, Surat, Gujarat - 395 002.
4. Dr. Chinta Srinivasa Rao, Lalitha Super Specialties Hospital (P) Ltd., Kothapet, Guntur, Andhra Pradesh - 522 001.
5. Dr. Sheela Thorat, Mediciti Hospital, 5-9-22, Secretariat Road, Hyderabad 500063.
6. Dr. Vidhut K Jain, Choithram Hospital & Research Centre, Manik Bagh Road, Indore-452 014.
7. Dr. Charan Lanjewar, King Edward Memorial VIII Hospital & Seth G.S Medical College, 4th Floor CVTC Building, Dept. of Cardiology, Acharya Donde Marg Parel, Mumbai 400 012.
8. Dr. Mukund Kumbla, Omega Hospital, Mahaveer Circle, Kankanady, Mangalore- 575 002.
9. Dr. Malipeddi Bhaskara Rao, Queen's NRI Hospital, Gurudwara Lane, Seethammadhara, Visakhapatnam – 530 013, Andhra Pradesh.
10. Dr. Milind Gadkari, KEM Hospital, 489, Rasta peth, Sardar Moodliar Road, Pune – 411 011.
11. Dr. Abhyankar Atul Damodar, Nirmal Hospital Pvt. Ltd, Ring Road, Surat - 395 002, Gujarat.

12. Dr. Keshav Prabhu, Chinmaya Narayana Supercpeciality Centre, CMH Road, Indiranagar, Bangalore 560 038.
13. Dr. Sameer Dani, Life Care Institute of Medical Science & Research, Sardar Patel statue corner, Naranpura. Ahmedabad – 380 014.
14. Dr. Sunil Thanvi, Bhanubhai & Madhuben Cardiac Centre, Shree Krishna Hospital and Medical Research Centre, Gokal Nagar, Karamsad, Gujarat -25.
15. Dr. Aniruddha Dharmadhikari, Shree Saibaba Heart Institute and Research Center, Near Kalidas kala mandir, Shalimar, Nashik.
16. Dr. Kunal Jhaveri, Sanjeevani Super Speciality Hospital, 1, Uday Park Society, Nr. Sunrise Park, Vastrapur, Ahmedabad-380 015.
17. Dr. Parag M Savsani, SAL Hospital, Opposite Doordarshan, Drive-in-road, Ahemedabad – 380 054.
18. Dr. Ashwani Mehta, Sir Ganga Ram Hospital, Sir Ganga Ram Hospital Marg, Rajinder Nagar, New Delhi-110 060.
19. Dr. Manisha S Dhobe, Ruby Hall Clinic, 40 Sassoon Road, Pune -411 001.
20. Dr. Ganesh Mathan, Yashoda Hospital, Raj Bhavan Road, Somajiguda, Hyderabad – 500 082.
21. Dr. Rakesh Kumar Aggarwal, Deep Heart Centre, Deep Hospital, 478-L, Model Town, Ludhiana (Pb) 141002.
22. Dr. D.K. Agarwal, Department of Cardiology, S.P. Medical college & A.G. Hospitals, Bikaner, Rajasthan.
23. Dr. Vikas Bisne, Meditrina Institute of Medical Science, 278, Central Bazar Road, Ramdaspeth, Nagpur - 440 010.
24. Dr. Sujit S Kadam, Shatabdi Superspeciality Hospital, Suyojit City Centre, Opp. Mahamarg Bus stand, Mumbai Naka, Nashik – 422 005.
25. Dr. Vinodkumar M Vijan, Vijan Cardiac & Critical Care Centre, Dr. Vijan Hospital Marg, College Road, Nashik – 422 005.

Kindly note that the clinical trial permission is subject to the following conditions:

a. Clinical trial shall be conducted in compliance with the approved protocols, requirements of Schedule Y, Good Clinical Practice Guidelines issued by this Directorate and other applicable regulations;

b. Approval of the Ethics Committee shall be obtained before initiation of the study;

c. Clinical trials shall be registered at Clinical trials Registry of India before enrolling the first patient for the study;

d. Annual status report of each clinical trial, as to whether it is ongoing, completed or terminated, shall be submitted to the Licensing Authority, and in case of termination of any clinical trial the detailed reasons for the same shall be communicated to the said Licensing Authority;

e. Any report of serious adverse event occurring during clinical trial study to the subject, after due analysis, shall be forwarded within ten days of its occurrence as per Appendix XI and in compliance with the procedures prescribed in Schedule Y;

f. In case of an injury or death during the study to the subjects, the applicant shall provide complete medical management and compensation in the case of trial related injury or death in accordance with rule 122 DAB and the procedures prescribed under Schedule Y, and the details of compensation provided in such cases shall be intimated to the Licensing Authority within thirty days of the receipt of the order of the said authority;

g. The premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites shall be open to inspection by the officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to verify compliance to the requirements of Schedule Y, Good Clinical Practices guidelines for conduct of clinical trial in India and other applicable regulations;

h. The Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial study sites and the Investigator shall allow officers authorized by the Central Drugs Standard Control Organization, who may be accompanied by an officer of the State Drug Control Authority concerned, to enter with or without prior notice, any premises of Sponsor including their employees, subsidiaries and branches, their agents, contractors and sub-contractors and clinical trial sites to inspect, search and seize any record, data, document, books, investigational drugs, etc. related to clinical trial and provide adequate replies to any queries raised by the inspecting authority in relation to the conduct of clinical trial.

i. Clinical trial shall be conducted only at those sites which are institutes/hospitals having adequate emergency facilities and duly registered Institutional Ethics committees.

j. The sponsor shall ensure that the number of clinical trials an investigator can undertake should be commensurate with the nature of the trial, facility available with the Investigator etc. However, under no circumstances the number of trials should be more than three at a time.

k. The details of payment/honorarium/financial support/fees paid by the Sponsor to the Investigator(s) for conducting the study shall be made available to this directorate before initiation of each of the trial sites.

l. An audio-video recording of the informed consent process in case of vulnerable subjects in clinical trials of New Chemical Entity or New Molecular Entity including procedure of providing information to the subject and his understanding on such consent, shall be maintained by the investigator for record. Provided that in case of clinical trial of anti-HIV and anti-Leprosy drugs, only audio recording of the informed consent process of individual subject including the procedure of providing information to the subject and his understanding on such consent shall be maintained by the investigator for record.

m. It may kindly be noted that merely granting permission to conduct clinical trials with the drug does not convey or imply that based on the clinical trial data generated with the drug, permission to market this drug in the country will automatically be granted to you.

Yours faithfully,

(Dr. V.G. Somani)
Joint Drugs Controller (India) &
Licensing Authority